Association between B‑Myb proto‑oncogene and the development of malignant tumors (Review)
- Authors:
- Yuelei Jin
- Gangqiao Qi
- Guang Chen
- Chen Wang
- Xiaoyan Fan
-
Affiliations: Department of Basic Medical Sciences, Taizhou University, Taizhou, Zhejiang 318000, P.R. China, Department of Sleep Medicine Center, Taizhou Second People's Hospital, Taizhou, Zhejiang 317200, P.R. China, Department of Respiratory Medicine, Municipal Hospital Affiliated to Medical School of Taizhou University, Taizhou, Zhejiang 318000, P.R. China - Published online on: January 4, 2021 https://doi.org/10.3892/ol.2021.12427
- Article Number: 166
-
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Oh IH and Reddy EP: The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 18:3017–3033. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lipsick JS and Wang DM: Transformation by v-Myb. Oncogene. 18:3047–3055. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Toscani A, Mettus RV, Coupland R, Simpkins H, Litvin J, Orth J, Hatton KS and Reddy EP: Arrest of spermatogenesis and defective breast development in mice lacking A-myb. Nature. 386:713–717. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Sala A: B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer. 41:2479–2484. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Iness AN, Felthousen J, Ananthapadmanabhan V, Sesay F, Saini S, Guiley KZ, Rubin SM, Dozmorov M and Litovchick L: The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. Oncogene. 38:1080–1092. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Musa J, Aynaud MM, Mirabeau O, Delattre O and Grünewald TG: MYBL2 (B-Myb): A central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 8:e28952017. View Article : Google Scholar : PubMed/NCBI | |
|
Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC and Perou CM: In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 28:742–751. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Long EM, Long MA, Tsirigotis M and Gray DA: Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor. Lung Cancer. 42:9–21. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, Tomasi ML, Seddaiu MA, Feo F and Pascale RM: Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J Hepatol. 55:111–119. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, et al: ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 6:28440–28452. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A: Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 62:6803–6807. 2002.PubMed/NCBI | |
|
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI | |
|
Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y, Song F and Bu Y: B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int J Mol Sci. 18:8602017. View Article : Google Scholar | |
|
Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin H and Cao F: B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell. Med Oncol. 32:4122015. View Article : Google Scholar : PubMed/NCBI | |
|
Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L and Powell CA: Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 163:1949–1960. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, et al: Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol Res. 38:886–895. 2008.PubMed/NCBI | |
|
Skotheim RI, Monni O, Mousses S, Fossa SD, Kallioniemi OP, Lothe RA and Kallioniemi A: New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res. 62:2359–2364. 2002.PubMed/NCBI | |
|
Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei P, Wang Y, Qi P, Shen C, Sheng W and Du X: MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res. 5:1542–1552. 2015.PubMed/NCBI | |
|
Qin HD, Liao XY, Chen YB, Huang SY, Xue WQ, Li FF, Ge XS, Liu DQ, Cai Q, Long J, et al: Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet. 98:709–727. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qin H, Li Y, Zhang H, Wang F, He H, Bai X and Li S: Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma. OncoTargets Ther. 12:1917–1927. 2019. View Article : Google Scholar | |
|
Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschellà G and Sala A: Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget. 1:278–288. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sala A, Casella I, Bellon T, Calabretta B, Watson RJ and Peschle C: B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. J Biol Chem. 271:9363–9367. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Arsura M, Introna M, Passerini F, Mantovani A and Golay J: B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood. 79:2708–2716. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Sala A and Calabretta B: Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc Natl Acad Sci USA. 89:10415–10419. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Lv QL, Huang YT, Zhang LH and Zhou HH: Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res. 36:1052017. View Article : Google Scholar : PubMed/NCBI | |
|
Sakai N, Kubota Y and Shuin T: Statistically significant expression of B-myb in clinically advanced human renal-cell carcinomas. Int J Oncol. 2:419–423. 1993.PubMed/NCBI | |
|
Nord H, Segersten U, Sandgren J, Wester K, Busch C, Menzel U, Komorowski J, Dumanski JP, Malmström PU and Díaz de Ståhl T: Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer. 126:1390–1402. 2010.PubMed/NCBI | |
|
Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME and Secchiero P: miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 17:2712–2724. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liang HB, Cao Y, Ma Q, Shu YJ, Wang Z, Zhang F, Ye YY, Li HF, Xiang SS, Song XL, et al: MYBL2 is a potential prognostic marker that promotes cell proliferation in gallbladder cancer. Cell Physiol Biochem. 41:2117–2131. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B and Sala A: Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem. 275:21055–21060. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD and Whittaker SJ: Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 101:1513–1519. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tao D, Pan Y, Lu H, Zheng S, Lin H, Fang H and Cao F: B-myb is a gene implicated in cell cycle and proliferation of breast cancer. Int J Clin Exp Pathol. 7:5819–5827. 2014.PubMed/NCBI | |
|
Martin CM, Astbury K, Kehoe L, O'Crowley JB, O'Toole S and O'Leary JJ: The use of MYBL2 as a novel candidate biomarker of cervical cancer. Methods Mol Biol. 1249:241–251. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Calvisi DF, Simile MM, Ladu S, Frau M, Evert M, Tomasi ML, Demartis MI, Daino L, Seddaiu MA, Brozzetti S, et al: Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology. 53:1226–1236. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Iltzsche F, Simon K, Stopp S, Pattschull G, Francke S, Wolter P, Hauser S, Murphy DJ, Garcia P, Rosenwald A and Gaubatz S: An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene. 36:110–1121. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas C, Robinson C, Dessauvagie B, Wood B, Sterrett G, Harvey J and Amanuel B: Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory. J Clin Pathol. 70:25–32. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wolter P, Hanselmann S, Pattschull G, Schruf E and Gaubatz S: Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy. Oncotarget. 8:11160–11172. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Diepenbruck M and Christofori G: Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lang G, Gombert WM and Gould HJ: A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology. 114:25–36. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ, Lee EK, Seo YE, Shin YH, Kim HS, Chun YH, Yoon JS, Kim HH, Han MY, Kim CK, et al: Roles of Bcl-2 and caspase-9 and −3 in CD30-induced human eosinophil apoptosis. J Microbiol Immunol Infect. 50:145–152. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Grassilli E, Salomoni P, Perrotti D, Franceschi C and Calabretta B: Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. Cancer Res. 59:2451–2456. 1999.PubMed/NCBI | |
|
Levenson VV, Davidovich IA and Roninson IB: Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res. 60:5027–5030. 2000.PubMed/NCBI | |
|
Sottile F, Gnemmi I, Cantilena S, D'Acunto WC and Sala A: A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget. 3:535–545. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Iida M, Brand TM, Campbell DA, Li C and Wheeler DL: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 32:759–767. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fuster O, Llop M, Dolz S, García P, Such E, Ibáñez M, Luna I, Gómez I, López M, Cervera J, et al: Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leuk Res. 37:1690–1696. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Raschella G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, Tonini GP, De Bernardi B and Calabretta B: Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Cancer Res. 59:3365–338. 1999.PubMed/NCBI | |
|
Astbury K, McEvoy L, Brian H, Spillane C, Sheils O, Martin C and O'Leary JJ: MYBL2 (B-MYB) in cervical cancer: putative biomarker. Int J Gynecologic Cancer. 21:206–212. 2011. View Article : Google Scholar | |
|
Komiya R: Biogenesis of diverse plant phasiRNAs involves an miRNA-trigger and Dicer-processing. J Plant Res. 130:17–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez I, Cazalla D, Almstead LL, Steitz JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez I and Dimaio D: B-Myb, cancer, senescence, and microRNAs. Cancer Res. 71:5370–5373. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Z, Huang X, Huang X, Zou Q and Guo Y: The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI | |
|
Geng GJ, Yang YT, Jiang J, Yu XY and Fa XE: MicroRNA-30a suppresses non-small-cell lung cancer by targeting Myb-related protein B. Exp Ther Med. 15:1633–1639. 2018.PubMed/NCBI | |
|
Li ZB, Chu HT, Jia M and Li L: Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family. Biochem Biophys Res Commun. 525:581–588. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YJ, Kang YR, Lee SY, Jin Y, Han DC and Kwon BM: Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of bMyb and miRNA34a expression. Int J Oncol. 51:1331–1342. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM and Matzuk MM: Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod. 91:1132014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, Zhou L, Zhou C, Yuan Q and Yang M: Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem. 290:3925–3935. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Tang X, Shi M, Wen C and Shen B: MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun. 483:816–822. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J and Chen X: MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol Res. 26:913–922. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lam EW, Robinson C and Watson RJ: Characterization and cell cycle-regulated expression of mouse B-myb. Oncogene. 7:1885–1890. 1992.PubMed/NCBI | |
|
de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R and Leone G: Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 278:42041–42049. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wong JV, Dong P, Nevins JR, Mathey-Prevot B and You L: Network calisthenics: Control of E2F dynamics in cell cycle entry. Cell Cycle. 10:3086–3094. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Giangrande PH and Nevins JR: Temporal control of cell cycle gene expression mediated by E2F transcription factors. Cell Cycle. 4:633–636. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson C, Light Y, Groves R, Mann D, Marias R and Watson R: Cell-cycle regulation of B-Myb protein expression: Specific phosphorylation during the S phase of the cell cycle. Oncogene. 12:1855–1864. 1996.PubMed/NCBI | |
|
Mowla SN, Lam EW and Jat PS: Cellular senescence and aging: The role of B-MYB. Aging Cell. 13:773–779. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue K and Fry EA: Novel molecular markers for breast cancer. Biomark Cancer. 8:25–42. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lam EW, Bennett JD and Watson RJ: Cell-cycle regulation of human B-myb transcription. Gene. 160:277–281. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Lam EW and Watson RJ: An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:2705–2713. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Lukas J, Petersen BO, Holm K, Bartek J and Helin K: Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol. 16:1047–1057. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Sala A, Saitta B, De Luca P, Cervellera MN, Casella I, Lewis RE, Watson R and Peschle C: B-MYB transactivates its own promoter through SP1-binding sites. Oncogene. 18:1333–1339. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Müller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD and Helin K: E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 15:267–285. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Infante A, Laresgoiti U, Fernandez-Rueda J, Fullaondo A, Galán J, Díaz-Uriarte R, Malumbres M, Field SJ and Zubiaga AM: E2F2 represses cell cycle regulators to maintain quiescence. Cell Cycle. 7:3915–3927. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Joaquin M and Watson RJ: Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci. 60:2389–2401. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Santilli G, Schwab R, Watson R, Ebert C, Aronow BJ and Sala A: Temperature-dependent modification and activation of B-MYB: Implications for cell survival. J Biol Chem. 280:15628–15634. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Giangrande PH and Nevins JR: E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23:4615–4626. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu Y, Zhu H and Bu Y: B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci. 19:14792018. View Article : Google Scholar |
